Prostatic and Peripheral Blood Selenium Levels After Oral Supplementation

Gianduzzo, Troy; Holmes, Earle W.; Tinggi, Ujang; Shahin, M.; MacTaggart, Peter; Nicol, David

doi:10.1097/01.ju.0000081052.51707.cf

Cited by 35 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An intriguing previous finding in 25 prostate cancer patients who had radical prostatectomies (12) indicated significantly higher concentrations of selenium in the peripheral zone, in which prostate cancer generally develops, than in the transitional zone; this finding, however, did not involve supplementation. There has been only one previous randomized study of selenium supplementation examining levels in the human prostate, which examined only (and found increased selenium in) the transitional zone (11). Our randomized, controlled study found that selenium supplementation resulted in increased selenium levels in the peripheral zone, in which prostate cancer develops most frequently (40), and that selenium accumulated selectively in the prostate instead of the SV.…”

Section: Discussionmentioning

confidence: 63%

“…The previous evaluations of selenium in human prostate (10 -13) and other tissues (14) lacked controls for differentiating between the effects of dietary versus supplemental selenium, or analyzed very few prostate tissue samples (15). We are aware of only one prior randomized study of supplemental selenium that examined selenium levels in prostate tissue (11). The limitations of the study included the availability of only transitional zone prostate tissue (from patients undergoing transurethral resection for benign prostatic hypertrophy), no sampling of other tissues to assess selectivity of selenium uptake in prostate tissue, and lack of control for chronic (dietary) selenium intake.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study

Sabichi

Lee

Taylor

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue. Experimental Design: We conducted a randomized, controlled, short-term trial of l-selenomethionine (SeMet) versus observation in men with organ-confined prostate cancer. The primary endpoint was the measurement of selenium concentration in prostate tissue and seminal vesicle (SV).We assessed baseline selenium levels in serum and in toenail specimens (reflecting long-term intake) and post-intervention selenium levels in serum, and in prostate and SV tissues using hydride generation atomic fluorescence spectroscopy. Results: Sixty-six eligible patients were randomly assigned to the SeMet (n = 34) or observation (n = 32) arm; both arms had similar baseline patient characteristics. Baseline serum selenium was similar in the two groups (P = 0.64). Baseline toenail selenium levels were slightly higher in the SeMet group than in the control group (P = 0.07). After the intervention, the mean serum selenium level increased 15% in the SeMet arm and was higher than in the observation arm (P = 0.001). The selenium concentration in prostate tissue was 22% higher in the SeMet arm (n = 26) than in the observation arm (n = 25; 1.80 versus 1.47 ppm; P = 0.003, Wilcoxon rank sum test) and remained significantly higher after adjusting for chronic selenium intake (P = 0.021, ANCOVA). SV selenium concentration was similar in both groups (P = 0.384) and was lower than in prostate tissue. Conclusions: The present study is the first to show that selenium taken as oral supplementation accumulates preferentially in the human prostate gland as opposed to the SV. These findings support the hypothesis that oral selenium supplementation may contribute to the cancer preventive effects of selenium.

show abstract

Section: Discussionmentioning

confidence: 63%

mentioning

confidence: 99%

Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study

Sabichi

Lee

Taylor

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Beguin et al [25,26] reported that tumors could, depending on "tumor activity," retain Se and serum Se level in patients with acute nonlymphocytic leukemia. Gianduzzo et al [27] showed that men who received daily oral Se supplementation for 30 d have statistically significant higher concentrations of Se in the prostate than those receiving a placebo, although the Se levels in the prostate and peripheral blood were poorly correlated. In this study, 7 d treatment with escalating doses of MSC was associated with sequential increases of intratumoral Se concentrations in both FaDu and A253 tumors (Fig.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent

Azrak

Cao

Pendyala

et al. 2007

Biochemical Pharmacology

View full text Add to dashboard Cite

This study was designed to understand the basis for the efficacy of methylselenocysteine (MSC) in increasing the therapeutic index of irinotecan against human tumor xenografts. Nude mice bearing human FaDu and A253 tumors were treated orally with different doses of MSC and irinotecan. Plasma, tumor and normal tissue samples were collected at different times after MSC treatments and were analyzed for selenium (Se) concentration using electrothermal atomic absorption spectrophotometry. MSC is highly effective in modulating the therapeutic index of irinotecan in the treatment of human squamous cells carcinoma of the head and neck xenografts (FaDu and A253). Enhanced irinotecan efficacy was greater in FaDu tumors (100% CR) than in A253 tumors (60% CR), and depended on MSC dose with a minimum effective dose of 0.01 mg/d x 28. The highest plasma Se concentration was achieved 1 h after a single dose and 28 d after daily treatments of MSC. The ability of FaDu tumors to retain Se was significantly better than A253 tumors, and the highest Se concentration in normal tissue was achieved in the liver. Peak plasma and tissue Se concentrations were functions of the dose and duration of MSC treatment. The MSC-dependent increase in Se level in normal tissues may contribute to the protective effect against irinotecan toxicity observed in those tissues. Intratumoral total Se concentration was not found to be predictive of the combination therapy response rates. There is a critical need to develop a method to measure the active metabolite of MSC, rather than total Se.

show abstract

“…This might be taken as an indirect indication in favor of selenium supplementation for the purpose of PC prevention. Two studies showed that oral administration of selenium, in comparison to controls, lead to a significant increase in the PTSL [28,29], but not in the seminal vesicles [29].…”

Section: Discussionmentioning

confidence: 99%

Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH

et al. 2009

View full text Add to dashboard Cite

Prostatic and Peripheral Blood Selenium Levels After Oral Supplementation

Abstract: Oral selenium supplementation increases prostatic and peripheral blood levels in men in a nonselenium deficient population. Blood and prostate levels correlated poorly, suggesting that peripheral blood measurements are a poor indicator of prostatic selenium content.

Cited by 35 publications

References 15 publications

Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study

Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study

Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent

Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH

Contact Info

Product

Resources

About